bendamustine + carboplatin + dexamethasone

Bendamustine + carboplatin + dexamethasone is a multi-agent chemotherapy combination, often referred to as the BCD regimen. It is primarily used as a salvage therapy for relapsed or refractory peripheral T-cell lymphomas (PTCLs)[1][2][3]. - **Bendamustine** is an alkylating agent with additional antimetabolite properties, causing DNA crosslinking and cell death in both dividing and non-dividing cells[7][9]. - **Carboplatin** is a platinum-based chemotherapeutic that induces DNA crosslinks, leading to apoptosis. - **Dexamethasone** is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive effects; in oncology regimens, it helps reduce inflammation and manage side effects of chemotherapy[8]. The combination has demonstrated an overall response rate of 54% in relapsed/refractory PTCLs, with manageable toxicity profiles. The regimen may be considered for patients eligible for autologous stem cell transplantation (ASCT)[1].

Other names

BCD regimen